Join us at the Cardiovascular Expert Theaters to learn about PCSK9 inhibition and the unmet need in patients with poorly controlled LDL-C.

This event is not part of the official Scientific Sessions 2015 as planned by the AHA committee on Scientific Sessions Program.

Paul Thompson, MD
Harold Edward Bays, MD, FTOS, FACC, FACE, FNLA
Michael Koren, MD, FACC

With PCSK9 Inhibition
Efficacy, Safety, Tolerability and Dosing Options

PCSK9 Inhibition: Efficacy and Safety With Two Dosing Options
Harold Edward Bays, MD, FTOS, FACC, FACE, FNLA

PCSK9 Inhibition: Long-term Safety and Efficacy
Paul Thompson, MD

Scientific Sessions Program.

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Sanofi and Regeneron Expert Lectures Series

Sanofi and Regeneron Expert Lectures Series

New 5th

Booth 1599

10/16/15  4:59 PM

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

New 5th

Booth 1601

10/20/15  6:06 PM

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

PCSK9 = proprotein convertase subtilisin/kexin type 9.

12:00

Booth 1328

Join us at Booth 1328 to learn about PCSK9 inhibition and the unmet need in patients with poorly controlled LDL-C.

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

1:00

12:00 – 12:30

3:15

12:00 – 12:45

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

PCSK9 Inhibition: Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

1:00 – 1:30

3:30 – 4:00

10:30 – 11:00

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With Two Dosing Options
Harold Edward Bays, MD, FTOS, FACC, FACE, FNLA

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability of PCSK9 Inhibition
Michael Koren, MD, FACC

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC

©2015, Sanofi and Regeneron Pharmaceuticals, Inc.

Efficacy, Safety, and Tolerability With PCSK9 Inhibition
Norman Lepor, MD, FACC